Akorn To Buy VPI Holdings For $440 Mln In Cash - Quick Facts

(RTTNews) - Pharmaceutical company Akorn Inc. (AKRX) announced Friday that it agreed to acquire VPI Holdings Corp., the parent company of VersaPharm Inc., for $440 million in cash.

VersaPharm, a privately-held developer and marketer of multi-source prescription pharmaceuticals, has a focus in the niche therapeutic categories of dermatology, tuberculosis and hemophilia. VersaPharm has built a robust pipeline of over 20 products, including 11 ANDAs filed with the FDA, with an addressable IMS market value of over $700 million.

This acquisition is expected to add $90 million to $100 million in annual revenues and $0.10 to $0.12 in earnings per share, excluding new pipeline launches, deal amortization and acquisition-related expenses.

The transaction is expected to be immediately accretive to earnings.

Akorn said it intends to fund the transaction through approximately $445 million in term loan borrowings. Fully committed financing for the transaction has been provided by JPMorgan Chase Bank, N.A.

The acquisition will be subject to customary conditions, including termination of the waiting period under the provisions of the Hart-Scott-Rodino Antitrust Improvement Act of 1976, as amended.

Pending the satisfaction of such customary conditions, Akorn anticipates closing the transaction in the third quarter of 2014.